The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
MPE webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, MyelomaDecember 8, 2020
ASH 2020 | Certain people with blood cancers and COVID-19 infection vulnerable to severe illnessAL amyloidosis, Conferences, MyelomaDecember 6, 2020
ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, MyelomaDecember 5, 2020
ASH 2020 | Visit our poster on myeloma patient information needs and preferences at ASH 2020!Conferences, MPE, MyelomaDecember 5, 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?AL amyloidosis, MPE, MyelomaMay 8, 2020
